Several drugs targeting the CD47-SIRPα axis are being tested against multiple tumour types; these include Hu5F9, TTI-621, ALX-148, AO-176 and OSE-172.67 Of these, only Hu5F9 is currently being studied for neuroblastoma treatment in combination with dinutuximab in a first-in-human/first-in-child phase I trial (NCT04751383). This evidence concerns the gene CD47 and neoplasm.